Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) EBIT Margin (2022 - 2025)

Historic EBIT Margin for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to 2359.23%.

  • Orchestra BioMed Holdings' EBIT Margin fell 7035100.0% to 2359.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 2669.91%, marking a year-over-year decrease of 3992200.0%. This contributed to the annual value of 2437.49% for FY2024, which is 5713300.0% down from last year.
  • Orchestra BioMed Holdings' EBIT Margin amounted to 2359.23% in Q3 2025, which was down 7035100.0% from 2311.84% recorded in Q2 2025.
  • Orchestra BioMed Holdings' EBIT Margin's 5-year high stood at 592.15% during Q1 2022, with a 5-year trough of 6591.7% in Q4 2024.
  • Its 4-year average for EBIT Margin is 2298.8%, with a median of 2166.97% in 2024.
  • In the last 5 years, Orchestra BioMed Holdings' EBIT Margin plummeted by -38727200bps in 2023 and then soared by 18106200bps in 2024.
  • Over the past 4 years, Orchestra BioMed Holdings' EBIT Margin (Quarter) stood at 891.02% in 2022, then tumbled by -435bps to 4763.74% in 2023, then crashed by -38bps to 6591.7% in 2024, then soared by 64bps to 2359.23% in 2025.
  • Its EBIT Margin was 2359.23% in Q3 2025, compared to 2311.84% in Q2 2025 and 2179.84% in Q1 2025.